Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock?

MRNA has rallied over 550% in 2026 after positive Phase 3 trial data for intismeran, a personalized cancer vaccine co-developed with MRK to treat melanoma. The stock now trades near $200, but consensus analyst price targets sit around $77—a 61% discount to current levels—signaling the rally may have overshot fundamentals despite recent upgrades.

The Phase 3 results triggered a wave of bullish analyst revisions, yet the gap between price and Street targets suggests the market has priced in optimism well ahead of commercial clarity. Moderna's valuation has expanded faster than analyst conviction, a setup that historically leaves momentum names vulnerable to sharp reversals on any setback in trial progress or regulatory timelines.

Merck's partnership lends credibility to the melanoma program, but the current share price embeds near-flawless execution. Traders who missed the initial surge face unfavorable risk-reward at these levels, particularly with the stock trading more than 2.5 times above where analysts see fair value.